1
Orphan Designations
0 approved, 1 designated
0
FDA Approvals
0
Active Trials
3
Rare Diseases
across 4 areas
0
News (30d)
Quiet
3H (Suzhou) Pharmaceuticals Co., Ltd. is a company with 1 orphan drug designation across 3 rare diseases.
Disease-by-disease pipeline progression from orphan designation through clinical trials to FDA approval.
Source: FDA Orphan Drug Designations, ClinicalTrials.gov, Drugs@FDA
| Disease | Drug(s) | Stage |
|---|---|---|
| cholangiocarcinoma | N-(4-(4-Amino-7-cyano-1-methyl-3-(4-((4-methylpyrimidin-2-yl)oxy)phenyl)-1H-pyrrolo[3,2-c]pyridin-2-yl)-3-methylphenyl)methacrylamide | Des.TrialAppr. |
| intrahepatic cholangiocarcinoma | N-(4-(4-Amino-7-cyano-1-methyl-3-(4-((4-methylpyrimidin-2-yl)oxy)phenyl)-1H-pyrrolo[3,2-c]pyridin-2-yl)-3-methylphenyl)methacrylamide | Des.TrialAppr. |
| sarcomatous intrahepatic cholangiocarcinoma | N-(4-(4-Amino-7-cyano-1-methyl-3-(4-((4-methylpyrimidin-2-yl)oxy)phenyl)-1H-pyrrolo[3,2-c]pyridin-2-yl)-3-methylphenyl)methacrylamide | Des.TrialAppr. |
0% of portfolio targets high unmet need diseases
3
overlap in 2+ diseases
0/3
candidate diseases
0
avg importance: 0
0
affecting portfolio
0% of portfolio targets high unmet need diseases
3
overlap in 2+ diseases
0/3
candidate diseases
0
avg importance: 0
0
affecting portfolio